Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

There are no validated molecular biomarkers to identify newly-diagnosed individuals with chronic-phase chronic myeloid leukemia likely to respond poorly to imatinib and who might benefit from first-line treatment with a more potent second-generation tyrosine kinase inhibitor. Our inability to predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Nteliopoulos, Georgios, Bazeos, Alexandra, Claudiani, Simone, Gerrard, Gareth, Curry, Edward, Szydlo, Richard, Alikian, Mary, Foong, Hui En, Nikolakopoulou, Zacharoula, Loaiza, Sandra, Khorashad, Jamshid S., Milojkovic, Dragana, Perrotti, Danilo, Gale, Robert Peter, Foroni, Letizia, Apperley, Jane F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959189/
https://www.ncbi.nlm.nih.gov/pubmed/31073075
http://dx.doi.org/10.3324/haematol.2018.200220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959189/
https://www.ncbi.nlm.nih.gov/pubmed/31073075
http://dx.doi.org/10.3324/haematol.2018.200220

Ejemplares similares